Must Read Publications on Theranostics
The ICPO Foundation is excited to introduce a new resource for theranostic centers, a detailed list of recent publications in the field. This collection is designed to serve as a valuable reference for theranostic centers worldwide, offering insights into the latest research, innovations, and clinical practices. Stay updated with cutting-edge developments in theranostics and enhance your center's expertise with these essential references.
1. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.
Weber WA, Czernin J, Anderson CJ, et al.
J Nucl Med. 2020 Dec;61(Suppl 2):263S–272S.
pubmed.ncbi.nlm.nih.gov/33293447/
2. Radiotheranostics: a roadmap for future development.
Herrmann K, Schwaiger M, Lewis JS, et al.
Lancet Oncol. 2020 Mar;21(3):e146 - e156.
pubmed.ncbi.nlm.nih.gov/32135118/
3. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.
Czernin J, Calais J.
J Nucl Med Technol. 2020 Jun;48(Suppl 1):82S–83S.
pubmed.ncbi.nlm.nih.gov/32605963/
4. Present and future of target therapies and theranostics: refining traditions and exploring new frontiers-highlights from annals of Nuclear Medicine 2021.
Pini C, Gelardi F, Sollini M.
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3613–3621.
pubmed.ncbi.nlm.nih.gov/35870007/
5. Next generation radiotheranostics promoting precision medicine.
Pomykala KL, Hadaschik BA, Sartor O, et al.
Ann Oncol. 2023 Jun;34(6):507–519.
pubmed.ncbi.nlm.nih.gov/36924989/
6. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, et al.
N Engl J Med. 2021 Sep 16;385(12):1091–1103.
pubmed.ncbi.nlm.nih.gov/34161051/
7. Combining External Beam Radiotherapy and 177Lu-PSMA-617: Bench to Bedside.
Arbuznikova D, Klotsotyra A, Uhlmann L, et al.
Theranostics. 2024 Apr;14(6):2560–2572.
pubmed.ncbi.nlm.nih.gov/38646643/
8. Joint EANM/SNMMI Guideline for 177Lu-PSMA Radioligand Therapy.
Kratochwil C, Fendler WP, Eiber M, et al.
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830–2845.
pubmed.ncbi.nlm.nih.gov/37246997/
9. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.
Lawhn-Heath C, Hope TA, Martinez J, et al.
Lancet Oncol. 2022 Feb;23(2):e75–e87.
pubmed.ncbi.nlm.nih.gov/35114134/
10. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.
Graves SA, Hobbs RF.
Semin Radiat Oncol. 2021 Jan;31(1):37–44.
pubmed.ncbi.nlm.nih.gov/33246635/
11. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics center.
Herrmann K, Giovanella L, Santos A, et al.
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2300–2309.
pubmed.ncbi.nlm.nih.gov/35403861/
12. First-in-Human Study: 177Lu-FAP-2286 in Diverse Adenocarcinomas.
Baum RP, Schuchardt C, Singh A, et al.
J Nucl Med. 2022 Mar;63(3):415–423.
pubmed.ncbi.nlm.nih.gov/34168013/
13. Impact of Theranostics Tumor Board on Patient Management.
Prasad V, Kim H, Trikalinos N, et al.
J Nucl Med. June 2024, 65 (suppl 2) 242589.
jnm.snmjournals.org/content/65/supplement_2/242589
14. Clinical Relevance of Post-Therapy SPECT/CT in Prostate Cancer.
Prasad V, Kim H, Michalski J, et al.
J Nucl Med. June 2024, 65 (suppl 2) 242599
jnm.snmjournals.org/content/65/supplement_2/242599
15. Recent Advances and Challenges in Radiopharmaceutical Sciences in Oncology.
Lapi SE, Scott PJH, Windhorst AD, Baum RP, et al.
Lancet Oncology or ScienceDirect.
www.sciencedirect.com/science/article/abs/pii/S1470204524000305
16. Efficacy and Safety of 225Ac-PSMA-617 in mCRPC.
Yadav MP, Ballal S, Sahoo RK, et al.
Theranostics. 2020;10(20):9364–9377.
pubmed.ncbi.nlm.nih.gov/32802197/
17. Biodistribution and Comparison of 68Ga-FAPI and 18F-FDG PET/CT.
Ballal S, Yadav MP, Moon ES, et al.
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1915–1931.
pubmed.ncbi.nlm.nih.gov/33244617/
18. Production and regulatory issues for theranostics.
Giammarile F, Paez D, Zimmermann R, et al.
Lancet Oncol. 2024 Jun;25(6):e260–e269.
pubmed.ncbi.nlm.nih.gov/38821100/
19. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.
Scott AM, Zeglis BM, Lapi SE, et al.
Lancet Oncol. 2024 Jun;25(6):e250–e259.
pubmed.ncbi.nlm.nih.gov/38821099/
20. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
Hofman MS, Tran B, Feldman DR, et al.
J Nucl Med. 2024 May;65(5):740–743.
pubmed.ncbi.nlm.nih.gov/38388517/
21. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225-labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)
Morris MJ, Wong JYC, Nordquist L, et al.
J Clin Oncol. 2024;42(16_suppl):5010.
doi.org/10.1200/JCO.2024.42.16_suppl.5010
22. Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar AP, Zerefa L, Yadav S, et al.
Theranostics. 2024 May;14(7):2969–2992.
pubmed.ncbi.nlm.nih.gov/38773983/
23. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.
Semin Nucl Med. 2024 Jul;54(4):537–556.
pubmed.ncbi.nlm.nih.gov/39019653/
24. Guiding principles on the education and practice of theranostics.
Pascual TNB, Paez D, Iagaru A, et al.
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320–2331
pubmed.ncbi.nlm.nih.gov/38453729/
25. Theranostics and artificial intelligence: new frontiers in personalized medicine.
Belge Bilgin G, Bilgin C, Burkett BJ, et al.
Theranostics. 2024 Mar;14(6):2367–2378.
pubmed.ncbi.nlm.nih.gov/38646652/
26. Immune Response to Molecular Radiotherapy with 177Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome.
Kluge A, Baum RP, Bitterlich N, et al.
Cancer Biother Radiopharm. 2024 Sep;39(7):541–550.
pubmed.ncbi.nlm.nih.gov/38905126/
27. Theranostics: Timing is Everything.
Turner JH.
Cancer Biother Radiopharm. 2024 Nov;39(9):611–618.
pubmed.ncbi.nlm.nih.gov/38757676/
28. Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.
Deroose C.M., Baum R.P., et al.
J Neuroendocrinol. 2024 Dec 9:e13479.
pubmed.ncbi.nlm.nih.gov/39653582/
29. Total-Body PET/CT: Pros and Cons.
Hicks RJ, Ware RE, Callahan J
Journal: Academic Radiology, 2024
www.sciencedirect.com/science/article/pii/S0001299824000655
30. The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases.
James N, Tannock I, N'Dow J, Feng F, Gillessen S, et al.
Journal: The Lancet. 2024
www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900651-2/fulltext
31. PSMA PET–Detected Disease Extent and Overall Survival in High-Risk Nonmetastatic Castration-Resistant Prostate Cancer: An International Multicenter Retrospective Study.
Weber M, Fendler WP, Kumar ASR, Calais J, Czernin J, et al.
Journal: Eur Urol. 2024
doi.org/10.1016/j.eururo.2024.01.019
32. Baseline Nodal Status on 68Ga-PSMA-11 PET/CT in Intermediate- to High-Risk Prostate Cancer: Prognostic Value from the proPSMA Trial.
Hofman M, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, et al.
Journal:Eur Urol Oncol. 2024
euoncology.europeanurology.com/article/S2588-9311%2824%2900251-7/fulltext
33. Management of Patients with Advanced Prostate Cancer: 2024 APCCC Report.
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, et al.
Journal: Eur Urol. 2024
www.sciencedirect.com/science/article/pii/S0302283824026101
34. Advances and Challenges in Precision Imaging.
Hricak H, Mayerhoefer ME, Herrmann K, Lewis JS, Pomper MG, et al.
Journal: Lancet Oncol. 2024
www.sciencedirect.com/science/article/pii/S1470204524003954
35. Intraarterial Administration of Peptide Receptor Radionuclide Therapy in Advanced Meningioma: Initial Safety and Efficacy.
Amerein A, Maurer C, Kircher M, Gäble A, Krebold A, et al.
Journal of Nuclear Medicine December 2024, 65 (12) 1911-1916; DOI:
doi.org/10.2967/jnumed.124.268217
36. Expression Prevalence and Dynamics of GPCR Somatostatin Receptors 2 and 3 as Cancer Biomarkers Beyond NET: A Paired IHC Approach.
Oron-Herman M, Kirmayer D, Lupp A, et al.
Sci Rep 13, 20857 (2023).
doi.org/10.1038/s41598-023-47877-0
37. Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor–Expressing Metastatic Breast Cancer.
Ulaner GA, VanderMolen LA, Li G, Ferreira D
Journal: Radiology. 2024;312(1):e233408
38. SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
Hope TA, Calais J, Goenka AH, et al.
J Nucl Med. 2025 Jan;66(1):26-33.
pubmed.ncbi.nlm.nih.gov/39572227/
39. First-in-human SPECT/CT imaging of [211At]PSMA-5: Targeted alpha therapy in refractory prostate cancer.
Hofman MS, Tran B, Watabe T, et al.
Eur J Nucl Med Mol Imaging. 2024 Dec 17.
pubmed.ncbi.nlm.nih.gov/39688698/
40. Overall survival with [177Lu]Lu-PSMA-617 vs. cabazitaxel in mCRPC (TheraP trial – secondary outcomes).
Hofman MS, Emmett L, Sandhu S, et al.
Lancet Oncol. 2024 Jan;25(1):99-107.
pubmed.ncbi.nlm.nih.gov/38043558/
41. First-in-human safety, imaging, and dosimetry of [68Ga]Ga-DPI-4452 in ccRCC.
Hofman MS, Tran B, Feldman DR, et al.
J Nucl Med. 2024 Feb;65(5):740-743.
pubmed.ncbi.nlm.nih.gov/38388517/
42. LuTectomy: [177Lu] Lu-PSMA-617 prior to radical prostatectomy in high-risk localized prostate cancer.
Eapen RS, Buteau JP, Jackson P, et al.
Eur Urol. 2024 Mar;85(3):217-226.
pubmed.ncbi.nlm.nih.gov/37891072/
43. [177Lu] Lu-PSMA-617 + Enzalutamide in mCRPC (ENZA-p trial).
Emmett L, Subramaniam S, Crumbaker M, et al.
Lancet Oncol. 2024 May;25(5):563-571.
pubmed.ncbi.nlm.nih.gov/38621400/
44. PSMA PET-detected disease extent & OS in high-risk nonmetastatic CRPC: Multicenter retrospective study.
Weber M, Fendler WP, Ravi Kumar AS, et al.
Eur Urol. 2024 Jun;85(6):511-516.
pubmed.ncbi.nlm.nih.gov/38490855/
45. UpFrontPSMA trial: Sequential [177Lu] Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
Azad AA, Bressel M, Tan H, et al.
Lancet Oncol. 2024 Oct;25(10):1267-1276.
pubmed.ncbi.nlm.nih.gov/39293461/
46. Advanced Prostate Cancer Management: 2024 APCCC Consensus Report.
Gillessen S, Turco F, Davis ID, et al.
Eur Urol. 2025 Feb;87(2):157-216.
pubmed.ncbi.nlm.nih.gov/39394013/
47. Radiotherapy and Theranostics: A Lancet Oncology Commission.
May Abdel-Wahab et al.
Lancet Oncol. 2024 Nov;25(11):e545-e580.
pubmed.ncbi.nlm.nih.gov/39362232/
48. Baseline Nodal Status on ⁶⁸Ga-PSMA-11 PET/CT in Intermediate- to High-risk Prostate Cancer is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
Michael S. Hofman et al.
Eur Urol Oncol. Published online 2024 Nov 28.
pubmed.ncbi.nlm.nih.gov/39613566/
49. First Clinical Experience of ⁶⁸Ga-FAPI PET/CT in a Tertiary Cancer Center: Identifying Pearls and Pitfalls.
Akram Al-Ibraheem et al.
Diagnostics (Basel). 2025 Jan 19;15(2):218.
pubmed.ncbi.nlm.nih.gov/39857102/
50. Overall Survival and Quality of Life with [¹⁷⁷Lu]Lu-PSMA-617 plus Enzalutamide versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer (ENZA-p Trial).
Louise Emmett et al.
Lancet Oncol. 2025 Mar;26(3):291–299.
pubmed.ncbi.nlm.nih.gov/39956124/
51. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from the Nuclear Medicine Global Initiative.
Akram Al-Ibraheem et al.
J Nucl Med. Published online 2025 Mar 27.
pubmed.ncbi.nlm.nih.gov/40147850/
52. FDA Expands Pluvicto’s Metastatic Castration-resistant Prostate Cancer Indication.
News Article